Clinical Relevance of Magnetic Resonance Imaging in Acute ST-Elevation Myocardial Infarction

Medical University Innsbruck2 sites in 1 country1,500 target enrollmentJanuary 2011

ConditionsAcute ST-Elevation Myocardial Infarction

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Acute ST-Elevation Myocardial Infarction
Sponsor: Medical University Innsbruck
Enrollment: 1500
Locations: 2
Primary Endpoint: Occurence of major adverse cardiovascular events
Status: Recruiting
Last Updated: 4 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

Cardiovascular magnetic resonance imaging enables comprehensive assessment of cardiovascular function, morphology and pathology. The investigators aim to evaluate the nature and clinical significance of magnetic resonance imaging parameters in patients presenting with first acute ST-elevation myocardial infarction.

Registry

clinicaltrials.gov

Start Date

January 2011

End Date

June 2031

Last Updated

4 years ago

Study Type

Observational

Sex

All

Investigators

Sponsor

Medical University Innsbruck

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Outcomes

Primary Outcomes

Occurence of major adverse cardiovascular events

Time Frame: 1 - 5 years

Secondary Outcomes

Aortic pulse wave velocity and distensibility by phase contrast imaging(baseline, 4 months and 12 months)
Cardiac function by cine imaging(baseline, 4 months and 12 months)
Parameters of cardiac function by transthoracic echocardiography(baseline, 4 months and 12 months)
Cardiac autonomic function(baseline, 4 months and 12 months)
Infarct size assessment (% of left ventricular myocardial mass)(baseline, 4 months and 12 months)
Assessment of infarct transmurality grade (%) with late gadolinium enhancement imaging(baseline, 4 months and 12 months)
Occurence and area of microvascular obstruction(baseline)
Intramyocardial haemorrhage assessed by T2* imaging(baseline, 4 months and 12 months)
Tissue characterisation by T1, T2 and T2* Mapping(baseline, 4 months and 12 months)
Myocardial deformation by strain analysis(baseline, 4 months and 12 months)
Aortic pulse wave distensibility by phase contrast imaging(baseline, 4 months and 12 months)
Quality of life and invalidity assessment (Global Physical Activity Questionnaire)(1 - 5 years)
Biomarker release during the acute and subacute phase(baseline, 4 months and 12 months)
Plaque volume by 3D ultrasound(baseline, 12 months)
Chamber volumes by cine imaging(baseline, 4 months and 12 months)
Stroke volumes by phase contrast imaging(baseline, 4 months and 12 months)